ArticleSynthetic biology (Oxford, England)2020
Article in Synthetic biology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mycogenic Nanomaterials: What Fungal Nanoparticles Promise and What Still Holds Them Back.Journal of fungi (Basel, Switzerland) · 2026Review
- Fungal Innovations-Advancing Sustainable Materials, Genetics, and Applications for Industry.Journal of fungi (Basel, Switzerland) · 2025Review
- Cell-free biosensor with automated acoustic liquid handling for rapid and scalable characterization of cellobiohydrolases on microcrystalline cellulose.Synthetic biology (Oxford, England) · 2025Article
- A new era of synthetic biology-microbial community design.Synthetic biology (Oxford, England) · 2024Review
- Public biofoundries as innovation intermediaries: the integration of translation, sustainability, and responsibility.The Journal of technology transfer · 2024Article
- AssemblyTron: flexible automation of DNA assembly with Opentrons OT-2 lab robots.Synthetic biology (Oxford, England) · 2023Article
- Digital Innovation Enabled Nanomaterial Manufacturing; Machine Learning Strategies and Green Perspectives.Nanomaterials (Basel, Switzerland) · 2022Review
- Biosynthesis and synthetic biology of psychoactive natural products.Chemical Society reviews · 2021Review
- GEDpm-cg: Genome Editing Automated Design Platform for Point Mutation Construction inFrontiers in bioengineering and biotechnology · 2021Article
- An Analysis of Monitoring Solutions for CAR T Cell Production.Healthcare technology lettersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The increasing demand for bio-based compounds produced from waste or sustainable sources is driving biofoundries to deliver a new generation of prototyping biomanufacturing platforms. Integration and automation of the design, build, test and learn (DBTL) steps in centers like SYNBIOCHEM in Manchester and across the globe (Global Biofoundries Alliance) are helping to reduce the delivery time from initial strain screening and prototyping towards industrial production. Notably, a portfolio of producer strains for a suite of material monomers was recently developed, some approaching industrial titers, in a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.